Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neil Collinson

Showing results (11-20 of 30) with videos related to

Pageof 3
Sort By:
Seminars in Arthritis and Rheumatism|November 15, 2016
Incidence of outcomes potentially associated with corticosteroid therapy in patients with giant cell arteritisJessica C Wilson, Khaled Sarsour, Neil Collinson, et al.
Rheumatology and Therapy|May 13, 2018
Risk Associated with Cumulative Oral Glucocorticoid Use in Patients with Giant Cell Arteritis in Real-World Databases from the USA and UKSara Gale, Jessica C Wilson, Jenny Chia, et al.
Seminars in Arthritis and Rheumatism|January 2, 2017
Serious adverse effects associated with glucocorticoid therapy in patients with giant cell arteritis (GCA): A nested case-control analysisJessica C Wilson, Khaled Sarsour, Neil Collinson, et al.
Annals of the Rheumatic Diseases|November 9, 2012
Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patientsRonald F van Vollenhoven, Paul Emery, Clifton O Bingham, et al.
British Journal of Pharmacology|January 19, 2005
Anxiogenic properties of an inverse agonist selective for alpha3 subunit-containing GABA A receptorsJohn R Atack, Peter H Hutson, Neil Collinson, et al.
Seminars in Arthritis and Rheumatism|December 22, 2016
Newly diagnosed vs. relapsing giant cell arteritis: Baseline data from the GiACTA trialKatie Tuckwell, Neil Collinson, Sophie Dimonaco, et al.
Journal of Medicinal Chemistry|November 13, 2004
An orally bioavailable, functionally selective inverse agonist at the benzodiazepine site of GABAA alpha5 receptors with cognition enhancing propertiesMark S Chambers, John R Atack, Robert W Carling, et al.
Journal of Medicinal Chemistry|May 16, 2003
Identification of a novel, selective GABA(A) alpha5 receptor inverse agonist which enhances cognitionMark S Chambers, John R Atack, Howard B Broughton, et al.
The Lancet. Infectious Diseases|January 27, 2022
Combining baloxavir marboxil with standard-of-care neuraminidase inhibitor in patients hospitalised with severe influenza (FLAGSTONE): a randomised, parallel-group, double-blind, placebo-controlled, superiority trialDeepali Kumar, Michael G Ison, Jean-Paul Mira, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|April 7, 2006
Alpha5GABAA receptors mediate the amnestic but not sedative-hypnotic effects of the general anesthetic etomidateVictor Y Cheng, Loren J Martin, Erin M Elliott, et al.
Pageof 3

Showing results (11-20 of 30) with videos related to

Sort By:
Pageof 3
Seminars in Arthritis and Rheumatism|November 15, 2016
Incidence of outcomes potentially associated with corticosteroid therapy in patients with giant cell arteritisJessica C Wilson, Khaled Sarsour, Neil Collinson, et al.
Rheumatology and Therapy|May 13, 2018
Risk Associated with Cumulative Oral Glucocorticoid Use in Patients with Giant Cell Arteritis in Real-World Databases from the USA and UKSara Gale, Jessica C Wilson, Jenny Chia, et al.
Seminars in Arthritis and Rheumatism|January 2, 2017
Serious adverse effects associated with glucocorticoid therapy in patients with giant cell arteritis (GCA): A nested case-control analysisJessica C Wilson, Khaled Sarsour, Neil Collinson, et al.
Annals of the Rheumatic Diseases|November 9, 2012
Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patientsRonald F van Vollenhoven, Paul Emery, Clifton O Bingham, et al.
British Journal of Pharmacology|January 19, 2005
Anxiogenic properties of an inverse agonist selective for alpha3 subunit-containing GABA A receptorsJohn R Atack, Peter H Hutson, Neil Collinson, et al.
Seminars in Arthritis and Rheumatism|December 22, 2016
Newly diagnosed vs. relapsing giant cell arteritis: Baseline data from the GiACTA trialKatie Tuckwell, Neil Collinson, Sophie Dimonaco, et al.
Journal of Medicinal Chemistry|November 13, 2004
An orally bioavailable, functionally selective inverse agonist at the benzodiazepine site of GABAA alpha5 receptors with cognition enhancing propertiesMark S Chambers, John R Atack, Robert W Carling, et al.
Journal of Medicinal Chemistry|May 16, 2003
Identification of a novel, selective GABA(A) alpha5 receptor inverse agonist which enhances cognitionMark S Chambers, John R Atack, Howard B Broughton, et al.
The Lancet. Infectious Diseases|January 27, 2022
Combining baloxavir marboxil with standard-of-care neuraminidase inhibitor in patients hospitalised with severe influenza (FLAGSTONE): a randomised, parallel-group, double-blind, placebo-controlled, superiority trialDeepali Kumar, Michael G Ison, Jean-Paul Mira, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|April 7, 2006
Alpha5GABAA receptors mediate the amnestic but not sedative-hypnotic effects of the general anesthetic etomidateVictor Y Cheng, Loren J Martin, Erin M Elliott, et al.
Pageof 3